Community Practice Connections™

Community Practice Connections™: 2nd Annual International Congress on the Future of Neurology®

Burst CME

Burst CME™ – Optimizing Care of Parkinson's Disease: Part 2

Burst CME™ – Optimizing Care of Parkinson's Disease: Part 1

Enduring Activity

Updates in the Journey for Disease-Modifying Therapies for Alzheimer Disease

Online Case Investigations: Multidisciplinary Evaluations of Acute Hepatic Porphyria - How Can We Improve Recognition and Treatment?

<h2 style="text-align:center">Multiple Sclerosis: Identifying Appropriate Treatment Options and What&rsquo;s on the Horizon</h2>

<div style="text-align:center">Part 2 of a 3-module On-Demand CE Webinar Curriculum Program. 
&nbsp;</div>

<div style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px; text-align:center">This activity is supported by educational grants from 
Sanofi Genzyme and Biogen.</div>
 
Faculty Presenter 
 
Erica Marini, PharmD, MS, BCPS 
Clinical Pharmacist, Neurology 
University of Utah Health 
Salt Lake City, Utah 
&nbsp;
<hr /> 
Program Description 
Current disease-modifying therapy (DMT) modalities in multiple sclerosis (MS) must address exacerbations, modify disease course, and control symptoms, thus improving overall quality of life for patients. In addition, determining whether patients need additional treatment for symptom control not provided with DMT is another important component of MS management. Pharmacists have important roles on the multidisciplinary care team in steering discussions with clinicians around when to initiate or discontinue adjuvant therapies in patients with MS based on patient presentation and safety considerations. This second module in a 3-part series will review developing, currently approved, and pipeline agents as well as indications for use of available treatment options in various MS stages. 
 
Target Audience:&nbsp;Specialty, health system, retail, and managed care pharmacists. 
Type of Activity:&nbsp;Application 
Release date: July 30, 2020 
Expiration date: July 30, 2021 
Time to complete activity: 1.5 hours 
Fee: Free 
 
Educational Objectives 
At the completion of this activity, participants will be able to: 

<ul>
	<li>Identify appropriate treatments for MS exacerbations, disease-modifying therapy, and control of MS-related symptoms</li>
	<li>Compare and contrast medications that are FDA approved for MS as disease-modifying agents for management of MS</li>
	<li>Explore the safety and efficacy data for new and investigational drugs for MS in late-phase clinical trials</li>
</ul>
 
<img alt="acpe" src="https://ptce.s3.amazonaws.com/_media/_eblast/ACPE_Large.jpg" style="float:left; height:59px; width:60px" />Pharmacy Times&nbsp;Continuing Education&trade; is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-20-212-H01-P. The activity is available for CE credit through July 30, 2021. 
 
 
Instructions for Completing the Activity and Receiving CPE Credit 
To receive CPE credit, participants must complete the pretest, view the webinar in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date. 
&nbsp;
<hr /> 
Disclosures 
 
Erica Marini, PharmD, MS, BCPS, has no relevant financial relationships with commercial interests to disclose. 
 
Pharmacy Times&nbsp;Continuing Education&trade;&nbsp;Planning Staff&nbsp;&ndash; Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Dipti Desai, PharmD, CHPC; Crissy Wilson; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose. 
 
An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose. 
 
Educational Disclaimer 
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources. 
 
For questions about this internet CPE activity, please contact: 
<a href="mailto:ceinfo@pharmacytimes.com">ceinfo@pharmacytimes.com</a> 
Privacy Policy and Terms of Use Information: 
<a href="http://www.pharmacytimes.org/terms">www.pharmacytimes.org/terms</a>

Multiple Sclerosis: Identifying Appropriate Treatment Options and What's on the Horizon

<h2 style="text-align:center">Understanding the Progression of Multiple Sclerosis</h2>

<div style="text-align:center">Part 1 of a 3-module On-Demand CE Webinar Curriculum Program. 
&nbsp;</div>

<div style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px; text-align:center">This activity is supported by educational grants from 
Sanofi Genzyme and Biogen.</div>
 
Faculty Presenter 
 
Aimee M. Banks, PharmD, BCPS, MSCS 
Clinical Pharmacist, Multiple Sclerosis 
Vanderbilt University Medical Center 
Nashville, Tennessee 
&nbsp;
<hr /> 
Program Description 
The exact cause of multiple sclerosis (MS) is unknown, but environmental and genetic influences are thought to be two factors associated with higher risk for disease. MS has a varying clinical presentation ranging from relapsing to progressive, with the most distinct clinical subtypes including relapsing-remitting MS (85%-90% diagnosed), secondary progressive MS, and primary progressive MS (10%-15% diagnosed). Each presentation is associated with progressive physical disability and reduced cognitive ability. This first module in a 3-part series will establish underlying factors for disease progression, the various phases, and goals of treatment to improve the quality of life of patients with MS.&nbsp;&nbsp; 
 
Target Audience:&nbsp;Specialty, health system, retail, and managed care pharmacists. 
Type of Activity:&nbsp;Application 
Release date: July 30, 2020 
Expiration date: July 30, 2021 
Time to complete activity: 1.0 hour 
Fee: Free 
 
Educational Objectives 
At the completion of this activity, participants will be able to: 

<ul>
	<li>Examine the epidemiology, etiology, pathophysiology, and classification of multiple sclerosis (MS)</li>
	<li>Analyze clinical presentation of MS using knowledge of disease subtypes, severity, and progression milestones</li>
	<li>Determine goals of treatment to improve clinical outcomes for patients with MS</li>
</ul>
 
<img alt="acpe" src="https://ptce.s3.amazonaws.com/_media/_eblast/ACPE_Large.jpg" style="float:left; height:59px; width:60px" />Pharmacy Times&nbsp;Continuing Education&trade; is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-20-190-H01-P. The activity is available for CE credit through July 30, 2021. 
 
 
Instructions for Completing the Activity and Receiving CPE Credit 
To receive CPE credit, participants must complete the pretest, view the webinar in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date. 
&nbsp;
<hr /> 
Disclosures 
 
Aimee M. Banks, PharmD, BCPS, MSCS, has no relevant financial relationships with commercial interests to disclose. 
 
Pharmacy Times&nbsp;Continuing Education&trade;&nbsp;Planning Staff&nbsp;&ndash; Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Dipti Desai, PharmD, CHPC; Crissy Wilson; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose. 
 
An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose. 
 
Educational Disclaimer 
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources. 
 
For questions about this internet CPE activity, please contact: 
<a href="mailto:ceinfo@pharmacytimes.com">ceinfo@pharmacytimes.com</a> 
Privacy Policy and Terms of Use Information: 
<a href="http://www.pharmacytimes.org/terms">www.pharmacytimes.org/terms</a>

Understanding the Progression of Multiple Sclerosis

<h2 style="text-align:center">Treating Chronic Inflammatory Demyelinating Polyneuropathy With Immunoglobulin: Strategies for Appropriate Use and Accurate Dosing</h2>

<div style="text-align:center">A 1-hour enduring broadcast including patient counseling videos. 
&nbsp;</div>

<div style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px; text-align:center">This activity is supported by an educational grant&nbsp;from 
CSL Behring.</div>
 
Faculty Presenters 
 
Jerry Siegel, PharmD, FASHP 
Clinical Associate Professor 
College of Pharmacy 
The Ohio State University 
Columbus, Ohio 
 
Vice President 
Safe Medication Management Associates, Inc. 
East Greenwich, Rhode Island 
&nbsp;
<div style="margin-bottom:8pt; margin-left:0in; margin-right:0in; margin-top:0in; text-align:center">
<hr /></div>
 
Program Description 
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a degenerative disease in which patients have reduced functioning of the extremities resulting from peripheral nerve damage. Immunoglobulin therapies have made symptom improvement achievable in approximately 70% to 90% of patients. Immunoglobulin therapy options continue to expand with more refined manufacturing processes and products. The advent of subcutaneous (SC) immunoglobulin in CIDP treatment has been shown to be as effective as intravenous (IV) administration in maintaining disease stability. Specialty pharmacists are in a critical position to review immunoglobulin dosing schedules and infusion rates; determine when it is clinically appropriate to continue, stop, or switch therapy; and monitor adverse effects. The clinical practice videos throughout this activity will equip specialty pharmacists with knowledge about navigating the intricacies of IV and SC therapies available for patients with CIDP, coordinating treatment, and managing health care utilization and outcomes. 
 
Target Audience:&nbsp;Specialty pharmacists 
Type of Activity:&nbsp;Application 
Release date: July 7, 2020 
Expiration date: July 7, 2021 
Fee: Free 
 
Educational Objectives

<ul>
	<li>Examine the pathophysiology of chronic inflammatory demyelinating polyneuropathy (CIDP)</li>
	<li>Identify the uses of subcutaneous and intravenous immunoglobulin for CIDP and differentiate the appropriate dosing protocols for each</li>
	<li>Explore opportunities for specialty pharmacists to intervene in CIDP care</li>
</ul>
 
<img alt="acpe" src="https://ptce.s3.amazonaws.com/_media/_eblast/ACPE_Large.jpg" style="float:left; height:59px; width:60px" />Pharmacy Times&nbsp;Continuing Education&trade; is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-20-170-H01-P. The activity is available for CE credit through July 7, 2021. 
 
 
Instructions for Completing the Activity and Receiving CPE Credit 
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date. 
 
Disclosures 
 
Jerry Siegel, PharmD, FASHP, has the following relevant financial relationships with commercial interest to disclose: 
Consultant: Kedrion 
Speakers Bureau: Takeda 
 
Pharmacy Times&nbsp;Continuing Education&trade;&nbsp;Planning Staff&nbsp;&ndash; Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Kim Simpson, PharmD; Brianna Schauer, MBA; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose. 
 
Anonymous peer reviewers are used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose. 
 
Activity Disclaimer 
Pharmacy Times&nbsp;Continuing Education&trade; (PTCE) strives to provide the highest level of service. However, unforeseen circumstances may necessitate the rescheduling or cancellation of live events, including, but not limited to, webinars hosted by PTCE. PTCE reserves the right to cancel an event without notice. PTCE will not be responsible for any expenditure incurred due to the cancellation. 
 
Educational Disclaimer 
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources. 
 
For questions about this live CPE activity, please contact: 
<a href="mailto:ceinfo@pharmacytimes.com">ceinfo@pharmacytimes.com</a> 
Privacy Policy and Terms of Use Information: 
<a href="http://www.pharmacytimes.org/terms">www.pharmacytimes.org/terms</a>

Treating Chronic Inflammatory Demyelinating Polyneuropathy With Immunoglobulin: Strategies for Appropriate Use and Accurate Dosing

<h2 style="text-align:center">Examining Multiple Sclerosis Disease Progression, Healthcare Utilization, and New Treatment Data</h2>

<div style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px; text-align:center">This activity is supported by an educational grant from 
Celgene Corporation.</div>
 
Faculty Presenter 
 
Patty Taddei-Allen, PharmD, MBA, BCACP, BCGP 
Senior Director, Clinical Analytics 
WellDyne 
Lakeland, Florida 
&nbsp;
<div style="margin-bottom:8pt; margin-left:0in; margin-right:0in; margin-top:0in; text-align:center">
<hr /></div>
 
Program Description 
Multiple sclerosis (MS) is one of the most common neurological conditions in the world, and it has enormous impact on patients&rsquo; quality of life. As their disability progresses, patients with MS incur substantial economic burden&mdash;often exceeding $4 million in lifetime costs. The development of disease-modifying treatments may have the potential to delay the progressive disability associated with this incurable disease. This activity will review the novel mechanisms of action of emerging agents in the MS treatment landscape, as well as new long-term data that has implications in treatment decisions for patients with MS. Equipped with this knowledge, managed care professionals and specialty pharmacists can balance therapeutic efficacy and cost-effective treatment options to achieve optimal clinical response in patients with MS. 
 
Target audience:&nbsp;Managed care pharmacists 
Type of activity:&nbsp;Application 
Release date: July 6, 2020 
Expiration date: July 6, 2021 
Fee: Free 
 
Educational Objectives

<ul>
	<li>Examine the classifications of multiple sclerosis (MS) and each stage&rsquo;s associated disease progression</li>
	<li>Explore the MOA, safety and efficacy data, and clinical trial results for emerging agents, recently approved agents, and approved agents with new phase 4 data</li>
	<li>Express the costs of disease progression and disability associated with MS</li>
	<li>Determine strategies for implementing value-based models to improve outcomes among patients with MS</li>
</ul>
 
<img alt="acpe" src="https://ptce.s3.amazonaws.com/_media/_eblast/ACPE_Large.jpg" style="float:left; height:59px; width:60px" />Pharmacy Times&nbsp;Continuing Education&trade; is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-20-186-H01-P. The activity is available for CE credit through July 6, 2021. 
 
 
 
Instructions for Completing the Activity and Receiving CPE Credit 
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date. 
 
Disclosures 
 
Patty Taddei-Allen, PharmD, MBA, BCACP, BCGP, has the following relevant financial relationship with a commercial interest to disclose:

<ul>
	<li>Advisory board: Novo Nordisk</li>
</ul>
Pharmacy Times&nbsp;Continuing Education&trade;&nbsp;Planning Staff&nbsp;&ndash; Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Kimberly Simpson, PharmD; Ann Marciano; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose. 
 
Anonymous peer reviewers are used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose. 
 
Activity Disclaimer 
Pharmacy Times&nbsp;Continuing Education&trade; (PTCE) strives to provide the highest level of service. However, unforeseen circumstances may necessitate the rescheduling or cancellation of live events, including, but not limited to, webinars hosted by PTCE. PTCE reserves the right to cancel an event without notice. PTCE will not be responsible for any expenditure incurred due to the cancellation. 
 
Educational Disclaimer 
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources. 
 
For questions about this live CPE activity, please contact: 
<a href="mailto:ceinfo@pharmacytimes.com">ceinfo@pharmacytimes.com</a> 
Privacy Policy and Terms of Use Information: 
<a href="http://www.pharmacytimes.org/terms">www.pharmacytimes.org/terms</a> 
&nbsp;

Examining Multiple Sclerosis Disease Progression, Healthcare Utilization, and New Treatment Data

<h2 style="text-align:center">Improving Treatment Regimens in Pulmonary Arterial Hypertension: The Health-System Pharmacist&#39;s Role</h2>

<div style="text-align:center">A 2-hour CE-accredited article. 
&nbsp;</div>

<div style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px; text-align:center">This activity is supported by an educational grant from 
Actelion Pharmaceuticals US, Inc.</div>
 
Faculty 
 
Rebecca L. Attridge, PharmD, MSc, BCPS 
Professor 
University of the Incarnate Word Feik School of Pharmacy 
Department of Pharmacy Practice 
Adjunct Assistant Professor 
UT Health, Department of Medicine 
Division of Pulmonary Diseases and Critical Care Medicine 
San Antonio, Texas 
 
Rebecca D. Moote, PharmD, MSc, BCPS 
Clinical Associate Professor 
The University of Texas College of Pharmacy 
Division of Pharmacotherapy 
UT Health San Antonio 
San Antonio, Texas 
Adjunct Associate Professor 
UT Health San Antonio 
Department of Medicine 
San Antonio, Texas 
&nbsp;
<div style="margin-bottom:8pt; margin-left:0in; margin-right:0in; margin-top:0in; text-align:center">
<hr /></div>
 
Program Description 
Pulmonary arterial hypertension (PAH) is a rare and fatal disease characterized by narrowing of pulmonary arteries in the lungs. Treatment goals for PAH are focused on slowing clinical deterioration through symptom management and include improvement in exercise capacity, improvement in quality of life, and decreased mortality risk. Although treatment has advanced significantly with dual and triple regimens in PAH-targeted drug therapy, these therapies remain complex and have potential for drug interactions. Through this activity, pharmacists will be able to explain evidence supporting combination regimens and different treatment approaches that can dramatically improve adherence in and outcomes of patients with PAH to optimize their quality of life. 
 
Target Audience:&nbsp;Health-system pharmacists 
Type of Activity:&nbsp;Application 
Release date: June 29, 2020 
Expiration date: July 15, 2021 
Fee: Free 
 
Educational Objectives

<ul>
	<li>Explain the pathophysiology of pulmonary arterial hypertension (PAH), the World Health Organization classifications, and genetic contributors to disease severity</li>
	<li>Examine clinical evidence involving the use of dual and triple regimens in PAH management</li>
	<li>Explore the clinical efficacy, safety, dosing and administration of current and emerging PAH therapies</li>
	<li>Identify opportunities for health-system pharmacists to intervene in PAH care to improve patient outcomes</li>
</ul>
 
<img alt="acpe" src="https://ptce.s3.amazonaws.com/_media/_eblast/ACPE_Large.jpg" style="float:left; height:59px; width:60px" />Pharmacy Times&nbsp;Continuing Education&trade; is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.2 CEU) under the ACPE universal activity number number 0290-0000-20-160-H01-P. The activity is available for CE credit through July 15, 2021. 
 
 
Instructions for Completing the Activity and Receiving CPE Credit 
To receive CPE credit, participants must complete the pretest, read the article in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date. 
 
Disclosures 
The following contributors have no relevant financial relationships with commercial interests to disclose: 
 
Faculty 
Rebecca L. Attridge, PharmD, MSc, BCPS 
Rebecca D. Moote, PharmD, MSc, BCPS 
 
Pharmacy Times&nbsp;Continuing Education&trade;&nbsp;Planning Staff&nbsp;&ndash; Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Dipti Desai, PharmD, CHCP; Crissy Wilson; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose. 
 
An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose. 
 
Activity Disclaimer 
Pharmacy Times&nbsp;Continuing Education&trade; (PTCE) strives to provide the highest level of service. However, unforeseen circumstances may necessitate the rescheduling or cancellation of live events, including, but not limited to, webinars hosted by PTCE. PTCE reserves the right to cancel an event without notice. PTCE will not be responsible for any expenditure incurred due to the cancellation. 
 
Educational Disclaimer 
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources. 
 
For questions about this live CPE activity, please contact: 
<a href="mailto:ceinfo@pharmacytimes.com">ceinfo@pharmacytimes.com</a> 
Privacy Policy and Terms of Use Information: 
<a href="http://www.pharmacytimes.org/terms">www.pharmacytimes.org/terms</a> 
&nbsp;

Improving Treatment Regimens in Pulmonary Arterial Hypertension: The Health-System Pharmacist's Role

This activity is supported by an educational grant from CSL Behring.
<h2>Updates in Myasthenia Gravis Treatment for Specialty Pharmacists Feat. Patient Counseling Video Vignettes</h2>
 Faculty 
 
Michael Erdman, PharmD, BCPS 
Critical Care Pharmacist 
Neuroscience Intensive Care Unit 
UF Health Jacksonville 
Jacksonville, Florida 
 
Medical writing support for patient-pharmacist counseling videos: 
 
Jill E. Allen, PharmD, BCPS 
Medical Writer and Drug information Consultant 
Pin Oak Associates 
Salt Lake City, Utah 
 
Activity Overview 
Myasthenia gravis is a rare, progressive autoimmune disease that leads to muscle weakness which may affect the eyes, limbs, and respiratory muscles. Myasthenic crisis can cause worsening respiratory function resulting in intubation and, in some cases, death. Current treatment decisions depend upon disease severity and include acetylcholinesterase inhibitors, with escalation to steroids and immunosuppressive agents as well as immunomodulatory treatment using IVIG, SCIG or plasma exchange. This activity features clinical vignettes that will better familiarize pharmacists with the specialty medications available for the treatment and management of patients with myasthenia gravis. 
 
Educational Objectives 
At the completion of this activity, the participant will be able to:

<ul>
	<li>Examine the pathophysiology and disease progression of myasthenia gravis</li>
	<li>Explore the available treatment approaches for myasthenia gravis and myasthenic crisis</li>
	<li>Identify opportunities of intervention for specialty pharmacists to improve patient care and outcomes in management of myasthenia gravis</li>
</ul>
<img src="https://s3.amazonaws.com/ptce/_media/_image/MGlanding.png" style="height:190px; width:263px" /> 
Target Audience:&nbsp;Pharmacists 
Activity Type:&nbsp;Application 
Release Date:&nbsp;June 30, 2020 
Expiration Date:&nbsp;June 30, 2021&nbsp;&nbsp; 
Estimated Time to Complete Activity:&nbsp;2 hours 
 
<img alt="acpe" src="https://ptce.s3.amazonaws.com/_media/_eblast/ACPE_Large.jpg" style="float:left; height:59px; width:60px" />Pharmacy Times&nbsp;Continuing Education&trade; is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.2 CEUs) under the ACPE universal activity number 0290-0000-20-152-H01-P. The activity is available for CE credit through June 30, 2021. &nbsp;&nbsp;&nbsp;&nbsp; 
 
 
Instructions for Earning Credit 
 
If you successfully complete the posttest and the evaluation form, this information will be uploaded into CPE Monitor. You must complete these steps before the activity expires in order to receive your credit. You may view your credit within 48 hours at&nbsp;www.mycpemonitor.net. 
 
NOTE:&nbsp;Your CE credit will be automatically uploaded to CPE Monitor.Please ensure that your&nbsp;Pharmacy Times&reg; account is updated with your NABP e-profile ID number and your date of birth. Participation data will not be uploaded into CPE Monitor if you do not have your NABP e-profile ID number and date of birth entered into your profile on&nbsp;www.pharmacytimes.org. 
 
Disclosures 
The following contributors have no relevant financial relationships with commercial interests to disclose: 
 
Faculty 
Michael Erdman, PharmD, BCPS 
 
Medical Writer 
Jill E. Allen, PharmD, BCPS 
 
Pharmacy Times&nbsp;Continuing Education&trade; Planning Staff: 
Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Dipti Desai, PharmD, CHCP; Rose Namissa, PharmD, BCPS; Kelly McCormick; Susan Pordon; and Brianna Winters 
 
Pharmacy Times&reg;&nbsp;Editorial Staff 
Davy James 
 
Anonymous peer reviewers were part of the content validation and conflict resolution and have no relevant financial relationships with commercial interests to disclose.&nbsp; 
 
Educational Disclaimer 
Continuing professional education (CPE) activities sponsored by&nbsp;Pharmacy Times&nbsp;Continuing EducationTM&nbsp;are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources. 
 
For questions about this Internet CPE activity, please contact: 
ceinfo@pharmacytimes.com 
Privacy Policy and Terms of Use information: 
<a href="https://www.pharmacytimes.org/terms">https://www.pharmacytimes.org/terms</a> 
&nbsp;

Updates in Myasthenia Gravis Treatment for Specialty Pharmacists Feat. Patient Counseling Video Vignettes

This activity is supported by educational grants from CSL Behring and Grifols.
<h2>Chronic Inflammatory Demyelinating Polyneuropathy: Assessing the Application of Intravenous and Subcutaneous Immunoglobulin, Featuring a Patient Perspective</h2>
 A 1.5-hour Webcast. This live broadcast replaced the continuing education satellite program that was scheduled at the 2020 Specialty Pharmacy Summit hosted by Asembia. 
 
Faculty Presenters 
 
Christine Anderson 
Vice President of Specialty Products 
EnvisionRX 
 
Paul G. Mathew, MD, DNBPAS, FAAN, FAHS 
Assistant Professor of Neurology 
Harvard Medical School 
Boston, Massachusetts 
 
Jonathan Ogurchak, PharmD, CSP 
Founder &amp; CEO 
STACK 
Pittsburgh, Pennsylvania 
 
Gil Wolfe, MD 
Irvin and Rosemary Smith Professor and Chairman 
University at Buffalo Distinguished Professor 
Department of Neurology, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, SUNY 
Buffalo, New York 
 
Patient 
Dave Rosner 
East Setauket, New York 
 
Program Description 
Chronic inflammatory demyelinating polyneuropathy is a rare, debilitating, and degenerative neurologic illness characterized by progressive weakness due to peripheral nerve damage. Inflammation of nerve roots and peripheral nerves results in myelin sheath destruction and subsequent impairment of motor and sensory functioning of extremities. If left untreated, an estimated 30% of patients would eventually become wheelchair dependent. Current treatment options provide symptomatic improvement and include corticosteroids, immunosuppressive agents, intravenous and subcutaneous immunoglobulin, and plasma exchange. This activity will provide an overview of CIDP, including a discussion on the burden of illness on patient quality of life and economic effect due to health care usage, focus on the intricacies of CIDP management, and implications for specialty pharmacy. The presentation will include an interview with a patient describing his journey living with CIDP, navigating treatment, and experiences in interacting with pharmacists. 
 
Target Audience:&nbsp;Specialty pharmacists, payers, managed care professionals, pharmacy benefit managers 
Type of Activity:&nbsp;Application 
Release date: June 5, 2020 
Expiration date: June 5, 2021 
Fee: Free 
 
Educational Objectives

<ul>
	<li>Explain the pathophysiology of chronic inflammatory demyelinating polyneuropathy (CIDP)</li>
	<li>Differentiate between the uses of subcutaneous (SC) and intravenous (IV) immunoglobulin for CIDP</li>
	<li>Identify the appropriate dosing protocols for SC and IV immunoglobulin for CIDP</li>
	<li>Examine health care economics and opportunities for specialty pharmacists to intervene in CIDP care</li>
</ul>
 
<img alt="acpe" src="https://ptce.s3.amazonaws.com/_media/_eblast/ACPE_Large.jpg" style="float:left; height:59px; width:60px" />Pharmacy Times&nbsp;Continuing Education&trade; is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-20-158-H01-P. The activity is available for CE credit through June 5, 2021. 
 
 
Instructions for Completing the Activity and Receiving CPE Credit 
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date. 
Note: If you attended the live broadcast of this presentation in place of the 2020 Specialty Pharmacy Summit hosted by Asembia, you will not be permitted to claim credit for this CE. 
 
Disclosures 
 
Paul G. Mathew, MD, DNBPAS, FAAN, FAHS, has the following relevant financial relationships with commercial interests to disclose: 
Grant/Research Support: BioMobie 
Consultant: Allergan, Amgen, Avanir, Biohaven, ElectroCore, Ipsen, Lilly, Novartis, Promius, Revance, Satsuma, Stealth BioTherapeutics, Supernus, Takeda, Theranica, Teva, Upsher-Smith 
 
Gil I. Wolfe, MD, has the following relevant financial relationships with commercial interests to disclose: 
Consultant: Grifols, BPS 
Speaker&rsquo;s Bureau: Grifols 
 
Christine Anderson, RPh, and Jonathan Ogurchak, PharmD, CSP, have no relevant financial relationships with commercial interests to disclose. 
 
Pharmacy Times&nbsp;Continuing Education&trade;&nbsp;Planning Staff&nbsp;&ndash; Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Rose Namissa, PharmD, BCPS; Crissy Wilson; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose. 
 
An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose. 
 
Activity Disclaimer 
Pharmacy Times&nbsp;Continuing Education&trade; (PTCE) strives to provide the highest level of service. However, unforeseen circumstances may necessitate the rescheduling or cancellation of live events, including, but not limited to, webinars hosted by PTCE. PTCE reserves the right to cancel an event without notice. PTCE will not be responsible for any expenditure incurred due to the cancellation. 
 
Educational Disclaimer 
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources. 
 
For questions about this live CPE activity, please contact: 
<a href="mailto:ceinfo@pharmacytimes.com">ceinfo@pharmacytimes.com</a> 
Privacy Policy and Terms of Use Information: 
<a href="http://www.pharmacytimes.org/terms">www.pharmacytimes.org/terms</a> 
&nbsp;

Chronic Inflammatory Demyelinating Polyneuropathy: Assessing the Application of Intravenous and Subcutaneous Immunoglobulin, Featuring a Patient Perspective

This activity is supported by an educational grant from Biogen.
<h2>Improving Outcomes in Spinal Muscular Atrophy Through Institutional Guidelines: The Role of the Health-System Pharmacist</h2>
 Faculty 
 
John F. Brandsema, MD 
Child Neurologist 
Neuromuscular Section Head 
Children&rsquo;s Hospital of Philadelphia 
Assistant Professor of Clinical Neurology 
Perelman School of Medicine 
University of Pennsylvania 
Philadelphia, Pennsylvania 
 
Joyce P. Lee, PharmD, BCPS 
Pharmacy Manager, Clinical Services 
Department of Pharmacy&nbsp; 
Children&rsquo;s Hospital of Philadelphia 
Philadelphia, Pennsylvania 
 
Medical Writer 
 
Brittany Hoffmann-Eubanks, PharmD, MBA 
Founder and CEO 
Banner Medical LLC 
Frankfort, Illinois 
 
Additional Medical Writing Support 
 
Jennifer Miller, PharmD, BCOP 
Clinical Informatics Pharmacist 
Baptist Health South Florida 
Coral Gables, Florida 
 
Activity Overview 
Spinal muscular atrophy (SMA) is a rare disease with treatment options consisting of supportive care to slow or prevent respiratory failure and joint issues. Early diagnosis of SMA has been a necessity as treatments are challenging. However, disease-modifying therapies have the potential to change the management and disease course for patients with SMA. This activity will equip pharmacists with essential knowledge to perform an active role in the management of this disease through understanding the safe handling of SMA therapies, dosing and administration, and proper counseling points to patients with SMA and their caregivers. 
 
Educational Objectives 
At the completion of this activity, the participant will be able to:

<ul>
	<li>Explain the clinical presentation, diagnosis, prevalence, epidemiology, and pathophysiology of spinal muscular atrophy (SMA)</li>
	<li>Explore current and emerging therapeutic options for SMA, including risks and benefits associated with each</li>
	<li>Identify strategies the health-system pharmacist can implement through institutional guidelines and proper counseling points</li>
</ul>
 
Target Audience:&nbsp;Health-system pharmacists 
Activity Type:&nbsp;Application 
Release Date:&nbsp;May 11, 2020 
Expiration Date:&nbsp;May 11, 2021&nbsp;&nbsp; 
Estimated Time to Complete Activity:&nbsp;2.5 hours 
Fee: Free 
 
<img alt="acpe" src="https://ptce.s3.amazonaws.com/_media/_eblast/ACPE_Large.jpg" style="float:left; height:59px; width:60px" />Pharmacy Times&nbsp;Continuing Education&trade; is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.5 contact hours (0.25 CEU) under the ACPE universal activity number 0290-0000-20-116-H01-P. The activity is available for CE credit through May 11, 2021. 
 
 
Instructions for Earning Credit 
 
Read the CE article in its entirety. If you successfully complete the posttest and the evaluation form, this information will be uploaded into CPE Monitor. You must complete these steps before the activity expires in order to receive your credit. You may view your credit within 48 hours at&nbsp;www.mycpemonitor.net. 
 
NOTE:&nbsp;Your CE credit will be automatically uploaded to CPE Monitor. Please ensure that your&nbsp;Pharmacy Times&reg; account is updated with your NABP e-profile ID number and your date of birth. Participation data will not be uploaded into CPE Monitor if you do not have your NABP e-profile ID number and date of birth entered into your profile on www.pharmacytimes.org. 
 
Disclosures 
The following contributor has relevant financial relationships with commercial interests to disclose: 
 
Faculty 
John F. Brandsema, MD
<ul>
	<li>Grant/Research Support: Alexion, AveXis, Biogen, CSL Behring, Cytokinetics, Fibrogen, Pfizer, PTC Therapeutics, Sarepta, Summit, WaVe</li>
	<li>Consultant: Alexion, Audentes, AveXis, Biogen, Cytokinetics, Genentech, PTC Therapeutics, Sarepta, WaVe</li>
	<li>Speakers Bureau: AveXis, Biogen 
	&nbsp;</li>
</ul>
The following contributors have no relevant financial relationships with commercial interests to disclose: 
 
Faculty 
Joyce P. Lee, PharmD, BCPS 
 
Medical Writer 
Brittany Hoffmann-Eubanks, PharmD, MBA 
 
Additional Medical Writing Support 
Jennifer Miller, PharmD, BCOP 
 
Pharmacy Times&nbsp;Continuing Education&trade; Planning Staff: 
Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Dipti Desai, PharmD, CHCP; Liza Patel, PharmD, RPh; Crissy Wilson; Susan Pordon; and Brianna Winters 
 
Pharmacy Times&reg;&nbsp;Editorial Staff 
Colleen Hall 
 
Anonymous peer reviewers were part of the content validation and conflict resolution and have no relevant financial relationships with commercial interests to disclose.&nbsp; 
 
Educational Disclaimer 
Continuing professional education (CPE) activities sponsored by&nbsp;Pharmacy Times&nbsp;Continuing EducationTM&nbsp;are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources. 
 
For questions about this Internet CPE activity, please contact: 
<a href="mailto:ceinfo@pharmacytimes.com">ceinfo@pharmacytimes.com</a> 
Privacy Policy and Terms of Use information: 
<a href="http://www.pharmacytimes.org/terms">www.pharmacytimes.org/terms</a> 
&nbsp;

Improving Outcomes in Spinal Muscular Atrophy Through Institutional Guidelines: The Role of the Health-System Pharmacist

On-Demand CE Webcast 
 
This activity is supported by an educational grant from Lilly.
<h2>Migraine Prophylaxis and Treatment: Evolving Therapies and the Opportunity for Pharmacist Intervention</h2>
 A 1.5-hour CE webcast held in conjunction with the American Pharmacists Association 2020 Annual Meeting and Exposition. 
 
Faculty Presenters 
Jeffrey Fudin, PharmD, FCCP, FASHP, FFSMB 
Clinical Pharmacy Specialist 
Stratton VA Medical Center 
Albany, New York 
 
Paul G. Mathew, MD, DNBPAS, FAAN, FAHS 
Assistant Professor of Neurology 
Harvard Medical School 
Boston, Massachusetts 
 
Program Description: 
Migraine is a neurological disease that may be associated with incapacitating symptoms. It is ranked as the third most prevalent illness in the world and affects an estimated 1 billion individuals worldwide. Multiple abortive and prophylactic therapies for migraine headaches are available; however, optimizing treatment can be difficult given the variation in presentation among patients and associated treatment challenges. Fortunately, there have been many advancements in this field in recent years. A focus on calcitonin gene-related peptide (CGRP) as a target led to the approval of medications in new classes, including anti-CGRP monoclonal antibodies and CGRP receptor antagonists. The approval of a medication from a new class featuring selective serotonin (5-HT)1F receptor agonists expanded the treatment armamentarium further. In order to make appropriate interventions, it is essential that pharmacists have a clear understanding of the role of both traditional as well as recently available options to ensure patients are correctly assessed and managed. 
 
Target Audience: 
Health-system and retail pharmacists&nbsp; 
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
Type of Activity: 
Application 
 
Educational Objectives

<ul>
	<li>Examine the epidemiology, pathophysiology, etiology, and diagnostic and treatment challenges associated with migraine headaches</li>
	<li>Distinguish between traditional options and recent advancements for abortive and prophylactic therapies for migraine headaches&nbsp;</li>
	<li>Explore the role of the pharmacist in individualizing therapy for patients with migraine headaches to improve adherence and optimize health outcomes</li>
</ul>
 
<img alt="acpe" src="https://ptce.s3.amazonaws.com/_media/_eblast/ACPE_Large.jpg" style="float:left; height:59px; width:60px" />Pharmacy Times Continuing Education&trade; is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-20-096-H01-P. The activity is available for CE credit through April 3, 2021. 
 
 
Instructions for Completing the Activity and Receiving CPE Credit 
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date. 
 
Disclosures 
 
Faculty 
Jeffrey Fudin, PharmD, FCCP, FASHP, FFSMB, has the following relevant financial relationships with commercial interests to disclose: 
Advisory boards: AcelRx Pharmaceuticals, Bio Delivery Sciences International, Daiichi Sankyo, GlaxoSmithKline, Human Half-Cell, Inc, Quest Diagnostics, Salix Pharmaceuticals 
Collaborative presentations: GlaxoSmithKline 
Collaborative publications: Scilex Pharmaceuticals, Salix Pharmaceuticals 
Consultant: AcelRx Pharmaceuticals, Bio Delivery Sciences International, Daiichi Sankyo, Firstox Laboratories 
Speakers bureaus: AcelRx Pharmaceuticals, AstraZeneca, Daiichi Sankyo, Salix Pharmaceuticals 
 
Paul G. Mathew, MD, DNBPAS, FAAN, FAHS, has the following relevant financial relationships with commercial interests to disclose: 
Consultant: Allergan, Amgen, Avanir, BioMobie, Biohaven, ElectroCore, Ipsen, Lilly, Novartis, Promius, Revance, Satsuma, Stealth BioTherapeutics, Supernus, Takeda, Theranica, Teva, Upsher-Smith 
 
The following contributors have no relevant financial relationships with commercial interests to disclose: 
 
Pharmacy Times Continuing Education&trade; 
Planning Staff &ndash; Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Liza Patel, PharmD, RPh; Crissy Wilson; Susan Pordon; Brianna Winters 
 
An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose. 
 
Activity Disclaimer 
Pharmacy Times Continuing Education&trade; (PTCE) strives to provide the highest level of service. However, unforeseen circumstances may necessitate the rescheduling or cancellation of live events, including, but not limited to, webinars hosted by PTCE. PTCE reserves the right to cancel an event without notice. PTCE will not be responsible for any expenditure incurred due to the cancellation. 
 
Educational Disclaimer 
Continuing professional education (CPE) activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources. 
 
For questions about this live CPE activity, please contact: 
<a href="mailto:ceinfo@pharmacytimes.com">ceinfo@pharmacytimes.com</a> 
Privacy Policy and Terms of Use Information: 
<a href="https://www.pharmacytimes.org/terms">https://www.pharmacytimes.org/terms</a> 
&nbsp;

Migraine Prophylaxis and Treatment: Evolving Therapies and the Opportunity for Pharmacist Intervention

This activity is supported by an educational grant from Eisai. 
<img src="https://s3.amazonaws.com/ptce/_media/_image/PateintPerspective-Transparent (002).png" style="max-width:250px; width:100%" />
<h2>A Managed Care Review on Insomnia: Treatment Guidelines, Emerging Therapies, and the Need for Safe, Effective Options</h2>
 Release date: March 11, 2020 
Expiration date: March 11, 2021 
Estimated time to complete activity: 3.0 hours 
Type of activity: Application 
Medium: Print with Internet-based posttest, evaluation, and request for credit 
Fee: Free 
 
Intended Audience 
Pharmacists and managed care professionals 
 
Activity Overview 
Up to 40 million Americans are estimated to have some form of insomnia. Factors that contribute to making insomnia a substantial public health burden include high healthcare costs, impaired quality of life, and exacerbation of coexisting medical and psychiatric conditions. It has an especially negative impact on vulnerable patient groups, including menopausal women, the elderly population, active military personnel and veterans, and those with coexisting depression or anxiety. Despite guideline recommendations to provide cognitive behavioral therapy for insomnia (CBTI) as first-line treatment, a lack of trained providers has limited patient access to it. Digital CBTI products are beginning to fill that void. Prescription treatment options include benzodiazepines, benzodiazepine receptor agonist hypnotics, doxepin, and orexin receptor antagonists. Factors that should be considered in pharmacotherapy selection include the type of insomnia, patient factors, adverse effect potential, and drug interactions. This activity will help increase awareness among managed care professionals about the impact of insomnia on vulnerable patient groups, CBTI and pharmacologic treatment options to manage insomnia, the economic implications of various treatment options, and strategies for optimizing patient care through education and therapy monitoring. 
 
Educational Objectives 
Upon completion of this activity, participants will be able to:
<ul>
	<li>Characterize the burden of insomnia and its associated comorbidities.</li>
	<li>Examine treatment guidelines and differentiate current and emerging treatments, including efficacy and safety considerations.</li>
	<li>Explore costs associated with insomnia and patient population needs to identify potential management strategies.</li>
</ul>
 
Accreditation Statement 
<img alt="acpe" src="https://ptce.s3.amazonaws.com/_media/_eblast/ACPE_Large.jpg" style="float:left; height:59px; width:60px" />&nbsp;Pharmacy Times Continuing Education&trade; is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 3.0 contact hours (0.30 CEU) under the ACPE universal activity number 0290-0000-20-067-H01-P. The activity is available for CE credit through March 11, 2021. 
 
 
FACULTY 
 
Julie A. Dopheide, PharmD, BCPP, FASHP 
Professor of Clinical Pharmacy 
University of Southern California School of Pharmacy and Keck School of Medicine 
Los Angeles, California 
 
Mei T. Liu, PharmD, BCPP 
Clinical Assistant Professor 
Department of Pharmacy Practice and Administration 
Ernest Mario School of Pharmacy 
Rutgers, the State University of New Jersey 
Piscataway, New Jersey 
 
Clinical Psychiatric Pharmacist 
Department of Pharmacy 
Penn Medicine Princeton House Behavioral Health 
Princeton, New Jersey 
 
Patty Taddei-Allen, PharmD, MBA, BCACP, BCGP 
Senior Director, Clinical Analytics 
WellDyne 
Lakeland, Florida 
 
Clinical Assistant Professor 
University of Florida College of Pharmacy 
Gainesville, Florida 
 
MEDICAL WRITING &amp; EDITORIAL SUPPORT 
 
Jill E. Allen, PharmD, BCPS 
Pin Oak Associates 
Salt Lake City, Utah 
 
David Modrak, PhD 
Medical Writer 
Montville, New Jersey 
 
Patrick Stone 
Medical Editor 
Philadelphia, Pennsylvania 
 
Jenna Wood, PharmD 
Medical Writer 
Columbus, Ohio 
 
 
FACULTY DISCLOSURES 
Patty Taddei-Allen, PharmD, MBA, BCACP, BCGP, has the following relevant financial relationships with commercial interests to disclose:

<ul>
	<li>Advisory Board Member: Novo Nordisk</li>
</ul>
 
Julie A. Dopheide, PharmD, BCPP, FASHP, and Mei T. Liu, PharmD, BCPP, have no relevant financial relationships with commercial interests to disclose. 
 
MEDICAL WRITING &amp; EDITORIAL SUPPORT DISCLOSURES 
Jill E. Allen, PharmD, BCPS; David Modrak, PhD; Patrick Stone; and Jenna Wood, PharmD, have no relevant financial relationships with commercial 
interests to disclose. 
 
The American Journal of Managed Care&reg; Publishing Staff: Ida Delmendo, Ted Pigeon, Angelia Szwed, Monica Tran, Elizabeth Kukielka, and Andrea Szeszko have no relevant financial relationships with commercial interests to disclose. 
 
Pharmacy Times Continuing Education&trade; Planning Staff: Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Kimberly Simpson, PharmD; Crissy Wilson; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose. 
 
Disclosure Policy 
According to the disclosure policy of The American Journal of Managed Care&reg; and Pharmacy Times Continuing Education&trade;, all persons who are in a position to control content are required to disclose any relevant financial relationships with commercial interests. If a conflict is identified, it is the responsibility of Pharmacy Times Continuing Education&trade; to initiate a mechanism to resolve the conflict(s). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence. 
 
Disclosure of Unapproved/Off-Label Use 
The contents of this activity may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Participants should note that the use of these products outside current approved labeling is considered experimental and they are advised to consult prescribing information for these products. 
 
The information provided in this CE activity is for continuing medical and pharmacy education purposes only and is not meant to substitute for the independent medical or pharmacy judgment of a physician or pharmacist relative to diagnostic, treatment, or management options for a specific patient&rsquo;s medical condition. 
 
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of The American Journal of Managed Care&reg;, Pharmacy Times Continuing Education&trade;, or any of the companies that provided commercial support for this CE activity. 
 
Signed disclosures are on file at the office of The American Journal of Managed Care&reg;, Cranbury, New Jersey. 
&nbsp;

A Managed Care Review on Insomnia: Treatment Guidelines, Emerging Therapies, and the Need for Safe, Effective Options

This activity is supported by educational grants from Alkermes, Inc. and&nbsp;Otsuka America Pharmaceutical, Inc. and Lundbeck. 
 
On-demand CE-accredited Webinar
<h2>Strategies to Improve Schizophrenia Management Through Better Adherence and Relapse Prevention</h2>
 Faculty Presenter 
 
M. Lindsey Hedgepeth Kennedy, PharmD, BCPS, BCPP 
Clinical Psychiatric Pharmacy Specialist 
Residency Program Director 
PGY-2 Psychiatric Pharmacy Residency 
University of North Carolina (UNC) Hospitals 
Course Director 
Human Behavior in Health and Disease 
UNC Chapel Hill School of Medicine 
Chapel Hill, North Carolina 
 
Activity Overview 
Research has consistently shown reduced medication adherence in patients diagnosed with schizophrenia. While the exact non-adherence rate is unknown, it is estimated to be as high as 50% in the first year of treatment.&nbsp; Nonadherence in schizophrenia leads to reduced quality of life, higher rate of relapse and carries a poor prognosis. Various medications are available to manage the symptoms of this illness and are available in oral and injectable forms to be administered daily or up to every 3 months. In this activity, pharmacists will become familiar with strategies to assess and optimize medication management with a patient centered approach that will break down barriers to care and improve outcomes in this population. 
 
Educational Objectives 
Upon completion of this educational activity, participants will be able to:

<ul>
	<li>Describe the prevalence of medication nonadherence and risks of relapse in patients with schizophrenia</li>
	<li>Explain the importance of relapse prevention and strategies for improving medication adherence and outcomes in patients with schizophrenia</li>
	<li>Explore the disease and treatment attributes relevant to the selection of SGA-LAIs in the management of schizophrenia</li>
	<li>Identify the pharmacist&rsquo;s role in the clinical decision-making process and engagement of patients in self-management</li>
</ul>
 
<img alt="https://ptce.s3.amazonaws.com/_media/_eblast/ACPE_Large.jpg" src="https://ptce.s3.amazonaws.com/_media/_eblast/ACPE_Large.jpg" style="float:left; height:59px; width:60px" />Pharmacy Times&nbsp;Continuing Education&trade; is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1 contact hour (0.1 CEU) under the ACPE universal activity number 0290-0000-20-060-H01-P. The activity is available for CE credit through February 19, 2021. 
 
 
Target Audience:&nbsp;Retail pharmacists 
Type of Activity:&nbsp;Application 
Length of Webinar:&nbsp;1.0 hour 
Fee:&nbsp;Free 
 
Instructions for Completing the Activity and Receiving CPE Credit&nbsp; 
To receive CPE credit, participants must complete the pretest, view the webinar in its entirety, complete the posttest, and complete the online activity evaluation after the webinar has concluded. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date. 
 
Disclosures 
 
The following contributors have no relevant financial relationships with commercial interests to disclose: 
 
Faculty: 
M. Lindsey Hedgepeth Kennedy, PharmD, BCPS, BCPP 
 
Pharmacy Times&nbsp;Continuing Education&trade; Planning Staff:&nbsp;Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Rose Namissa, PharmD, BCPS; Crissy Wilson; Susan Pordon; and Brianna Winters have no financial relationships with commercial interests to disclose. 
Anonymous peer reviewers have been used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose. 
 
The content of this webinar may include information regarding the use of products that may be inconsistent with, or outside the approved labeling for, these products in the United States. Pharmacists should note that the use of these products outside current approved labeling is considered experimental and are advised to consult the prescribing information for these products.&nbsp;&nbsp; 
 
Educational Disclaimer&nbsp; 
Continuing education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources. 
&nbsp;